Nurse’s role in pharmacological pre-exposure prophylaxis of HIV infection

Introduction. Reducing the number of new HIV infections is one of the challenges of modern health care. Advances in medicine have given rise to new methods of preventing the transmission of the infection. Pharmacological pre-exposure prophylaxis (PrEP) is one of them.

Aim. The aim of this paper is to discuss the principles of PrEP and to bring the role of a nurse closer in this regard.

Method. The safety and effi cacy of PrEP have been demonstrated in clinical trials. At the same time, in accordance with the postulates of the WHO to transfer competencies related to the prevention of the spread of HIV to other health care professionals, models of PrEP provision by e.g. nurses, are being discussed.

Results. Pharmacological PrEP used in vulnerable groups at risk of HIV infection may help slow down the epidemic. Nurses have almost all the knowledge and clinical competence to provide PrEP services. Expanding the competence of nurses by including HIV diagnosis, prescription of medications approved for use as PrEP, and increasing the scope of decision-making in this type of prophylaxis will contribute to its popularisation in Poland, as well as increase the prestige of the profession and the possibilities of developing of advanced nursing practice.

Nurse’s role in pharmacological pre-exposure prophylaxis of HIV infection.pdf

References

1. WHO. Estimated number of people (all ages) living with HIV. Published online 11.10.2021 https://www.who.int/data/gho/data/indicators/indicator-details/GHO/ estimated-number-of-people--living-with-hiv (data dostępu: 12.10.2021)

2. Zakład Epidemiologii Chorób Zakaźnych i Nadzoru Narodowego Instytutu Zdrowia Publicznego – Państwowego Zakładu Higieny. Zakażenia HIV i zachorowania na AIDS w Polsce w latach 1996-2020. http://wwwold.pzh.gov.pl/oldpage/epimeld/ hiv_aids/index.htm (data dostępu: 12.10.2021).

3. Krajowe Centrum ds. AIDS Agenda Ministra Zdrowia. Kampanie społeczne. https:// aids.gov.pl/kampanie/kampanie-spoleczne/ (data dostępu: 12.10.2021).

4. Szetela B, Gąsiorowski J, Łapiński Ł. Profilaktyka przedekspozycyjna zakażenia HIV. [W:] Parczewski M, Jabłonowska E, Witak-Jędra M, i wsp. Zasady opieki nad osobami zakażonymi HIV. Zalecenia polskiego towarzystwa naukowego AIDS 2021. Polskie Towarzystwo Naukowe AIDS Warszawa-Szczecin 2021: 38-42.

5. Tsai CC, Follis K, Sabo A, et al. Prevention of SIV Infection in Macaques by (R)-9-(2Phosphonylmethoxypropyl)adenine. Science 1995; 270(5239): 1197-1199.

6. Cohen M, Kashuba A. Antiretroviral Therapy for Prevention of HIV Infection: New Clues From an Animal Model. PLoS Med. 2008 Feb; 5(2): e30.

7. Dobard C, Parikh U, Sharma S, et al. Complete protection against repeated vaginal simian HIV exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine [paper #46]. Presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal, Quebec, Canada.

8. Peterson L, Taylor D, Roddy R, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials. 2007 May 25; 2(5): e27.

9. Grohskopf L, Chillag K, Gyetadze R, et al. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr 2013 Sep 1; 64(1): 79-86.

10. Buchbinder S, Glidden D, Liu A, et al. HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial. Lancet Infect Dis. 2014; 14(6): 468-475.

11. Centers for Disease Control and Prevention: US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States–2017 Update: a clinical practice guideline. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prepguidelines-2017.pdf. Published March 2018.

12. Sivay MV, Li M, Piwowar-Manning E, et al. HPTN 067/ADAPT Study Team. Characterization of HIV seroconverters in a TDF/FTC PrEP study: HPTN 067/ADAPT. J Acquir Immune Defic Syndr 2017; 75: 271-279.

13. Grulich AE, Guy R, Amin J, et al. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study, The Lancet HIV 2018; 5(11): e629-e637.

14. Jana S, Ray P, Roy S, et al. Successful integration of HIV pre-exposure prophylaxis into a community-based HIV prevention program for female sex workers in Kolkata, India. Int J STD AIDS. 2021 Jun; 32(7): 638-647.

15. Wilson C. Massive drop in London HIV rates may be due to internet drugs. New Scientist 2017 Jan 14(3108); https://www.newscientist.com/article/2117426massive-drop-in-london-hiv-rates-may-be-due-to-internet-drugs/ (data dostępu: 12.10.2021).

16. U.S. Food & Drug Administration. FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention. 20.12.2021 https://www.fda.gov/news-events/pressannouncements/fda-approves-first-injectable-treatment-hiv-pre-exposureprevention ( data dostępu: 20.01.2022).

17. Choi H, Suh J, Lee W, et al. Cost-effectiveness analysis of pre-exposure prophylaxis for the prevention of HIV in men who have sex with men in South Korea: a mathematical modelling study Sci Rep. 2020; 10: 14609.

18. Alistar S, Grant P, Bendavid E. Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa BMC Med. 2014; 12: 46.

19. Suraratdecha C, Stuart R, Manopaiboon C, et al. Cost and cost‐effectiveness analysis of pre‐exposure prophylaxis among men who have sex with men in two hospitals in Thailand. J Int AIDS Soc. 2018 Jul; 21(Suppl Suppl 5): e25129.

20. Roberts A, Barnabas R, Abuna F, et al. The role of costing in the introduction and scale‐up of HIV pre‐exposure prophylaxis: evidence from integrating PrEP into routine maternal and child health and family planning clinics in western Kenya. J Int AIDS Soc. 2019 Jul; 22(Suppl Suppl 4): e25296.

21. Cambiano V, Miners A, Dunn D, et al. Is Pre-Exposure Prophylaxis for HIV prevention cost-effective in men who have sex with men in the UK? A modelling and health economic evaluation Lancet Infect Dis. 2018 Jan; 18(1): 85-94.

22. Bernard C, Brandeau M, Humphreys K, et al. Cost-Effectiveness of HIV Preexposure Prophylaxis for People Who Inject Drugs in the United States. Ann Intern Med. 2016 Jul 5;165(1):10-19.

23. Nichols BE, Boucher CAB, van der Valk M, et al. Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study. Lancet Infect Dis. 2016 Dec; 16(12): 1423-1429.

24. van de Vijver D, Richter A, Boucher C, et al. Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058. Euro Surveill. 2019 Feb 14; 24(7): 1800398.

25. Zhang L, Peng P, Wu Y, et.al. Modelling the Epidemiological Impact and Cost-Effectiveness of PrEP for HIV Transmission in MSM in China. AIDS Behav. 2019 Feb; 23(2): 523-533.

26. Peebles K, Mugwanya K, Irungu E, et al. Low costs and opportunities for efficiency: a cost analysis of the first year of programmatic PrEP delivery in Kenya’s public sector. BMC Health Serv Res. 2021; 21: 823.

27. World Health Organisation. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. World Health Organization Geneva 2021. https://www.who.int/ publications/i/item/9789240031593 (data dostępu: 17.02.2022).

28. Wojciechowska AM (red.) Zapobieganie zakażeniom HIV, opieka nad ludźmi żyjącymi z HIV i chorymi na AIDS, Centrum Edukacji Medycznej; Warszawa 1996.

29. Rogowska-Szadkowska D, Gąsiorowski J. HIV/AIDS dla pielęgniarek i położnych. Krajowe Centrum ds. AIDS. Agenda Ministra Zdrowia. 2013 https://aids.gov.pl/ publikacje/184/ (data dostępu: 17.02.2022).

30. Borowiak E, Bebel G. Opieka pielęgniarska nad osobami z chorobami zakaźnymi. [W:] Talarska D, Zozulińska-Ziółkiewicz D. Pielęgniarstwo internistyczne. PZWL; Warszawa 2017.

31. Minister Zdrowia- Krajowe Centrum ds. AIDS. Załącznik do uchwały nr 156/2016 Rady Ministrów z dnia 13 grudnia 2016 r. Harmonogram zadań realizowanych w ramach Krajowego Programu Zapobiegania Zakażeniom HIV i Zwalczania AIDS opracowany na lata 2017–2021. https://aids.gov.pl/wp-content/plugins/downloadattachments/includes/download.php?id=4943 (data dostępu 11.11.2021).

32. O’Byrne P, MacPherson P, Orser L, et al. PrEP-RN: Clinical Considerations and Protocols for Nurse-Led PrEP. J Assoc Nurses AIDS Care. 2019 May-Jun; 30(3): 301-311.

33. O’Byrne P, Orser L, Haines M. Active-Offer Nurse-Led PrEP (PrEP-RN) Referrals: Analysis of Uptake Rates and Reasons for Declining. AIDS Behav. 2020; 24: 1281-1289.

34. Kazakidis K, Kryczka T. Zaawansowana Praktyka Pielęgniarska jako panaceum systemu ochrony zdrowia w Polsce. Pielęgniarstwo XXI wieku 2021; 20(1): 50-57.

35. O’Byrne P, Vandyk A, Orser L, et al. Nurse-led PrEP-RN clinic: a prospective cohort study exploring task-Shifting HIV prevention to public health nurses. BMJ Open. 2021 Jan 7; 11(1): e040817.

36. Schmidt H-MA, McIver R, Houghton R, et al. Nurse-Led pre-exposure prophylaxis: a non-traditional model to provide HIV prevention in a resource-constrained, pragmatic clinical trial. Sex Health 2018; 15: 595-597.

37. Nelson LE, McMahon JM, Leblanc NM, et al. Advancing the case for nurse practitioner-based models to accelerate scale-up of HIV pre-exposure prophylaxis. Journal of Clinical Nursing 2019(28): 351-361.

38. Rabkin M, Lamb M, Osakwe ZT, et al. Nurse-led HIV services and quality of care at health facilities in Kenya, 2014-2016. Bull World Health Organ. 2017 May 1; 95(5): 353-361.

39. Charest M, Sharma M, Chris A, et al. (2021) Decentralizing PrEP delivery: Implementation and dissemination strategies to increase PrEP uptake among MSM in Toronto, Canada. PLoS ONE 16(3): e0248626.

40. Zhang C, Mitchell W, Xue Y, et al. Understanding the role of nurse practitioners, physician assistants and other nursing staff in HIV pre-exposure prophylaxis care in the United States: a systematic review and meta-analysis. BMC Nurs. 2020; 19: 117.

41. Stockton JM. Assessment for sexually transmitted infections in men who have sex with men attending a nurse-run HIV preexposure prophylaxis clinic. J Am Assoc Nurse Pract. 2021; Feb 18; 33(12): 1290-1294.

This work is licensed under a Creative Commons Attribution 4.0 International License.